WHWK — Whitehawk Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1422142 ·
Last close
$4.16
Market Cap
$205.72M
52W High
$5.49
52W Low
$3.15
ADV30
409,113
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -23,522,000 | -22,194,000 | 127,231,000 | 34,790,000 | 11,056,000 |
| Dec 2025 | 0 | 0 | -24,887,000 | -23,251,000 | 150,830,000 | 37,568,000 | 14,519,000 |
| Sep 2025 | 0 | 0 | -19,546,000 | -17,746,000 | 167,017,000 | 37,931,000 | 9,849,000 |
| Jun 2025 | 0 | 0 | -54,749,000 | -52,615,000 | 180,822,000 | 144,936,000 | 8,756,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-97,433,000
Investing CF
$11,891,000
Financing CF
$94,376,000
CapEx
$-926,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.47
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-353,250,000
Inventory
$0
Receivables
$0
ST Investments
$108,129,000
EBIT TTM
$-20,596,000
Pretax Income TTM
$-20,596,000
Interest Exp TTM
$0
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-122,681,000
Free Cash Flow
$-68,453,000
Enterprise Value
$82,679,248
Total Cash
$123,043,000
Total Debt
$0
Shares Out
49,452,463
Trailing EPS
$-2.49
Book Value
$2.89
ROE
-68.5%
ROA
-42.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 7,145,000 | -114,400,000 | -20,596,000 | 150,830,000 | 14,519,000 | — | -97,433,000 |
| Dec 2024 | 25,983,000 | -64,820,000 | -63,691,000 | 70,319,000 | 17,841,000 | — | -59,550,000 |
| Dec 2023 | 24,354,000 | -71,933,000 | -65,765,000 | 132,423,000 | 27,228,000 | — | -59,663,000 |
| Dec 2022 | 15,216,000 | -58,957,000 | -60,513,000 | 184,237,000 | 25,859,000 | — | -49,640,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.23
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $4.10 · call volume: 4 · put volume: 20
Expected Move to 2026-06-18:
±$1.25
(30.49%) —
implied range
$2.85 –
$5.35
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NKTX | Nkarta, Inc. | $204.62M | $2.86 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $204.01M | $4.05 | — |
| NGEN | NERVGEN PHARMA CORP. | $203.91M | $1.92 | — |
| NERV | Minerva Neurosciences, Inc. | $210.12M | $4.51 | — |
| KROS | Keros Therapeutics, Inc. | $200.89M | $10.15 | — |
News headlines (Yahoo Finance, 1h cache)
Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?
2026-06-10 18:22 · Yahoo
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
2026-05-30 18:30 · Yahoo
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
2026-05-28 20:05 · Yahoo
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
2026-05-26 22:26 · Yahoo
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise
2026-05-22 00:38 · Yahoo
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
2026-05-21 21:05 · Yahoo
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
2026-05-20 12:00 · Yahoo
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
2026-05-16 15:01 · Yahoo
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
2026-05-15 12:00 · Yahoo
May 2026's Promising Penny Stocks
2026-05-14 12:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.